Preclinical studies have demonstrated that BRG1 inactivation increases tumor invasiveness and enhances sensitivity to targeted agents inhibiting oxidative phosphorylation and drugs targeting EZH2, AURKA, ATR, CDK4, and CDK6. This evidence concerns the gene CDK6 and neoplasm.